Clinical characteristics and outcome in renal transplant recipients with bladder cancer.
- Author:
Jin Young KIM
1
;
Myong Jun SONG
;
Byung Ha CHUNG
;
Min Soo KIM
;
Hyei Young YOU
;
Young Soo KIM
;
Chul Woo YANG
;
Yong Soo KIM
;
In Sung MOON
;
Yong Bok KOH
;
Byung Kee BANG
Author Information
1. Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. yangch@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Bladder cancer;
Renal transplantation;
Kidney transplantion;
Hematuria
- MeSH:
Biopsy;
Cadaver;
Diagnosis;
Drug Therapy;
Hematuria;
Humans;
Incidence;
Kidney;
Kidney Transplantation;
Korea;
Living Donors;
Lost to Follow-Up;
Medical Records;
Radiotherapy;
Retrospective Studies;
Sarcoma, Kaposi;
Transplantation*;
Transplants;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Medicine
2003;64(4):435-441
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: With the rise in the number of renal transplantation procedures in the past years, the incidence of bladder cancer in transplant recipients has increased. This study undertaken to evaluate the clinical characteristics and outcome in renal transplant recipients with bladder cancer. METHODS: Since 1969, 1343 renal transplantations has been performed at catholic university medical college of korea. Of these patients, Nine developed bladder cancer with histologically confirmed by cystoscopic biopsy. We reviewed the medical records of nine renal transplant recipients who had bladder cancer retrospectively. RESULTS: Nine of 1343 renal transplant recipients developed bladder cancer. All patients were diagnosed histologically as bladder cancer. The median patient age at diagnosis of bladder cancer was 48 years, and the median interval between renal transplantation and diagnosis of malignancy was 8 years. The male/female ratio was 4/5. one patient received cadaver kidney and eight recieved living donor kidney. Seven patients had urothelial carcinoma and two had Kaposi sarcoma. Seven patients had a graft dysfunction and advanced stage of bladder cancer at the time of diagnosis of malignancy. All patients has microscopic or gross hematuria. They underwent operation only or operation and chemotherapy or operation and postoperative radiotherapy. Three patients died of progressive disease at a l year after diagnosis of malignancy, 1 patients were lost to follow-up, and 5 were still alive. CONCLUSION: Bladder cancer is not rare, and its occurrence is relatively young in renal transplant recipients. We recommend early workup of hematuria in the renal transplant recipient using the radiographic and cystoscopic evaluation.
